There is research on this stock available only to PRO subscribers.
The Company That Can Grow You A New Organ: A Promising Long-Term Investment
- HART's bioreactor and scaffold product has been used to regenerate the human trachea using stem cells. Around 10 human tracheae have been successfully implanted, saving patients' lives.
- The company has a proven management in the medical device sector with high alignment to shareholder interests.
- Orphan Designation has been granted by the FDA, giving the company a shortened pathway through clinical trials and a 7-year monopoly if approved.
- The company currently has a market cap of $47 million, while there's an addressable market of at least $600 million for regenerated tracheae after approval.
- The company is on the leading edge of regenerative medicine, with the regeneration of other vital organs in the pipeline.
Harvard Apparatus Regenerative Technology; A Strategic Plan To Profitability
- HART's strategic initiatives to profitability appear quite reasonable at this stage.
- HART's solution to tracheal cancer or trauma can be evaluated for efficacy within one year, the expected survival time remaining for patients with no other solution but surgical implantation.
- After the FDA or EU equivalent agency assigns “Orphan Status” to either a drug, durable medical equipment or device, speedier approvals and extended exclusivity awards are enjoyed by the applicant.
There are no Transcripts on HART.
Wed, Nov. 26, 12:49 PM
Fri, Mar. 14, 9:18 AM
- Nano cap regenerative medicine firm Harvard Apparatus Regenerative Technology (HART) is poised for an opening gap up.
- The stock broke out on March 4 on heavy volume. It peaked at $10.98 on March 11, a 100% gain from its previous high of $5.47.
- The firm posted an updated investor presentation on its website this morning.
- Financial results were disclosed on March 7.
- 71 mutual funds have positions.
Nov. 4, 2013, 8:45 AM
- Harvard Bioscience (HBIO) is off 16% premarket after completing a spin-off of its regenerative medicine device subsidiary.
- Harvard Apparatus Regenerative Technology now trades on the Nasdaq under the ticker HART.
- HBIO shareholders got one share of HART for every share of HBIO they owned as of October 21.
- HBIO now calls itself a "pure-play global developer, manufacturer and marketer of a broad range of tools to advance life science research." (PR)
- CEO Jeffrey Duchemin has been appointed President and Director, replacing David Green who is now HART's President.
HART vs. ETF Alternatives
Currently, there's no company description for HART.
Country: United States
Other News & PR